Design of Experimental Studies of Transmission of Creutzfeldt- Jakob Disease (CJD) by Plasma and Plasma Derivatives; Notice of Public Workshop

Riepilogo

The Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), is announcing a public workshop on design of experimental studies to investigate possible transmission of Creutzfeldt-Jakob Disease (CJD) by plasma and plasma derivatives. This scientific workshop, sponsored by FDA and the National Heart, Lung, and Blood Institute, is intended to foster an indepth discussion of the available laboratory methods which would underlie experimental studies on the transmission of CJD and related diseases by plasma and derived products.